Health Care & Life Sciences » Pharmaceuticals | Intra-Cellular Therapies Inc.

Intra-Cellular Therapies Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
37,150.90
129,645.70
475,200.30
384,100.70
464,331.00
347,530.50
Total Accounts Receivable
336.30
51.60
30.70
94.30
-
-
Other Current Assets
762.20
1,289.00
8,025.10
4,005.10
4,884.30
7,908.10
Total Current Assets
38,249.50
130,986.30
483,256.10
388,200.10
469,215.30
355,438.70
Net Property, Plant & Equipment
68.30
54.60
775.50
627.60
1,137.20
1,159.80
Other Assets
131.60
70.90
71.90
75.80
75.80
78.80
Total Assets
38,449.30
131,111.80
484,103.50
388,903.50
471,486.70
357,206.50
Accounts Payable
3,395.10
2,052.80
1,632.90
3,754.60
6,173.50
Other Current Liabilities
3,439.00
8,504.30
4,630.60
6,777.70
8,036.10
Total Current Liabilities
6,834.00
10,557.10
6,263.50
10,532.30
14,209.60
Deferred Taxes
-
-
-
-
1,058.40
Other Liabilities
-
-
1,597.10
2,868.60
2,840.10
Total Liabilities
6,834.00
10,557.10
7,860.60
13,401.00
17,049.70
Common Equity (Total)
31,615.30
120,554.70
476,242.90
375,502.50
454,437.00
Total Shareholders' Equity
31,615.30
120,554.70
476,242.90
375,502.50
454,437.00
Total Equity
31,615.30
120,554.70
476,242.90
375,502.50
454,437.00
Liabilities & Shareholders' Equity
38,449.30
131,111.80
484,103.50
388,903.50
471,486.70

About Intra-Cellular Therapies

View Profile
Address
430 East 29th Street
New York New York 10016
United States
Employees -
Website http://www.intracellulartherapies.com
Updated 07/08/2019
Intra-Cellular Therapies, Inc. is a biopharmaceutical company, which focuses on the discovery and clinical development of innovative, small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. Its lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. The company also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease, and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease.

StatInvestor

Privacy Policy
Feedback

© 2025 StatInvestor All Rights Reserved.